Can this have any impact on the market size of WCK 5222 (cefepime+zidebactam) developed by Wockhardt, mainly targeting hospital acquired infections, ventilator associated pneumonia and other gram negative suberbugs?
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
